Amarin Corporation plc is a commercial-stage pharmaceutical company focused on developing therapies, especially based on omega-3 fatty acid for treating cardiovascular diseases. The company's sole marketed drug, Vascepa (icosapent ethyl) is approved in the United States as an adjunct to diet for treating severe hypertriglyceridemia or elevated triglyceride levels. The FDA approved Vascepa to reduce cardiovascular risk in patients with persistent elevated triglycerides on statin therapy for LDL-C. The drug received approval for both indications in Europe under the tradename of Vazkepa. It has initiated various promotional activities and direct-to-consumer programs as well as expanded its salesforce to support promotion of Vascepa's expanded label. A generic version of Vascepa has been launched for elevated TG levels....
+See More2019-04-09 11:29:00 Tuesday ET
The U.S. Treasury yield curve inverts for the first time since the Global Financial Crisis. The key term spread between the 10-year and 3-month U.S. Treasur
2022-11-05 11:32:00 Saturday ET
CEO overconfidence and corporate performance Malmendier and Tate (JFE 2008, JF 2005) argue that overconfident CEOs are more likely to initiate mergers an
2019-09-01 10:31:00 Sunday ET
Most artificial intelligence applications cannot figure out the intricate nuances of natural language and facial recognition. These intricate nuances repres
2019-04-03 11:35:00 Wednesday ET
A Florida fintech group Fidelity Information Services initiates the largest $43 billion acquisition of the e-commerce payments processor Worldpay. Fidelity
2018-07-03 11:42:00 Tuesday ET
President Trump's current trade policies appear like the Reagan administration's protectionist trade policies back in the 1980s. In comparison to th
2017-02-25 06:44:00 Saturday ET
As the White House economic director, Gary Cohn suggests that the Trump administration will tackle tax cuts after the administration *repeals and replaces*